Characteristics of patients and grafts
| Parameter . | Total, n = 133 . |
|---|---|
| Patients | |
| Male | 74 (55.6) |
| Female | 59 (44.4) |
| Median age plus or minus SD, y (range) | 55.6 ± 9.4 (23.8-73.7) |
| Diagnoses | |
| CML | 11 (8.3) |
| CP1 | 8 |
| AP/BC | 3 |
| ALL | 3 (2.3) |
| CR2 | 1 |
| Relapse/refractory | 2 |
| MDS | 23 (17.3) |
| RA | 8 |
| RARS | 1 |
| RAEB/t, CMMoL (untreated) | 14 |
| AML | 29 (21.8) |
| CR1 | 6 |
| Relapse/primary refractory | 19 |
| CR2 or greater | 3 |
| Untreated | 1 |
| sAML | 29 (21.8) |
| CR1 | 2 |
| Relapse/refractory | 16 |
| Untreated | 11 |
| MPS/OMF | 9 (6.8) |
| Untreated/CP1 | 4 |
| CP2 | 1 |
| BC | 4 |
| Myeloma, all relapse/refractory/PR | 9 (6.8) |
| Lymphoma | 13 (9.8) |
| CR1 | 1 |
| CR2 or greater | 1 |
| Relapse/refractory/PR | 11 |
| CLL, all refractory | 7 (5.3%) |
| Remission status | |
| Total | 133 |
| Early | 27 (20.3) |
| Advanced | 106 (79.7) |
| AML/MDS | 81 |
| Early | 17 (21.0) |
| Advanced | 64 (79.0) |
| Donor type | 127 |
| Age, y (range) | 44.4 (20-74) |
| Related, fully matched | *68 (51.1) |
| Unrelated, fully matched | †59 (44.4) |
| Unrelated, minor HLA-mismatched | 6 (4.5) |
| Donor sex match | |
| Patient male/donor female | 31 (23.3) |
| Patient female/donor male | 33 (24.8) |
| Match | 69 (51.9) |
| CMV status | |
| Patient neg/donor neg | 23 (17.3) |
| Patient neg/donor pos | 18 (13.5) |
| Patient pos/donor neg | 36 (27.1) |
| Patient pos/donor pos | 45 (33.8) |
| NE | 1 (0.8) |
| GVHD prophylaxis | |
| CsA plus mMtx | ‡23 (17.3) |
| CsA plus MMF | §¶108 (81.2) |
| Graft | |
| Source | |
| Bone marrow | 15 (11.3) |
| Peripheral blood | 116 (87.2) |
| Both | 2 (1.5) |
| Values | |
| Bone marrow | |
| WBC, × 108 cells/kg (15 pt) | 3.7 (1.9-14.0) |
| CD34, × 106 cells/kg (13 pt) | 3.0 (1.0-9.6) |
| CD3, × 108 cells/kg (11 pt) | 0.5 (0.2-2.4) |
| Peripheral blood | |
| WBC, × 108 cells/kg (114 pt) | 13.5 (4.2-32.7) |
| CD34, × 106 cells/kg (116 pt) | 6.7 (1.7-14.0) |
| CD3, × 108 cells/kg (108 pt) | 2.8 (1.1-6.6) |
| Both | |
| WBC, × 108 cells/kg (2 pt) | 35.2 |
| CD34, × 06 cells/kg (2 pt) | 2.5 |
| CD3, × 108 cells/kg (2 pt) | 3.3 |
| Parameter . | Total, n = 133 . |
|---|---|
| Patients | |
| Male | 74 (55.6) |
| Female | 59 (44.4) |
| Median age plus or minus SD, y (range) | 55.6 ± 9.4 (23.8-73.7) |
| Diagnoses | |
| CML | 11 (8.3) |
| CP1 | 8 |
| AP/BC | 3 |
| ALL | 3 (2.3) |
| CR2 | 1 |
| Relapse/refractory | 2 |
| MDS | 23 (17.3) |
| RA | 8 |
| RARS | 1 |
| RAEB/t, CMMoL (untreated) | 14 |
| AML | 29 (21.8) |
| CR1 | 6 |
| Relapse/primary refractory | 19 |
| CR2 or greater | 3 |
| Untreated | 1 |
| sAML | 29 (21.8) |
| CR1 | 2 |
| Relapse/refractory | 16 |
| Untreated | 11 |
| MPS/OMF | 9 (6.8) |
| Untreated/CP1 | 4 |
| CP2 | 1 |
| BC | 4 |
| Myeloma, all relapse/refractory/PR | 9 (6.8) |
| Lymphoma | 13 (9.8) |
| CR1 | 1 |
| CR2 or greater | 1 |
| Relapse/refractory/PR | 11 |
| CLL, all refractory | 7 (5.3%) |
| Remission status | |
| Total | 133 |
| Early | 27 (20.3) |
| Advanced | 106 (79.7) |
| AML/MDS | 81 |
| Early | 17 (21.0) |
| Advanced | 64 (79.0) |
| Donor type | 127 |
| Age, y (range) | 44.4 (20-74) |
| Related, fully matched | *68 (51.1) |
| Unrelated, fully matched | †59 (44.4) |
| Unrelated, minor HLA-mismatched | 6 (4.5) |
| Donor sex match | |
| Patient male/donor female | 31 (23.3) |
| Patient female/donor male | 33 (24.8) |
| Match | 69 (51.9) |
| CMV status | |
| Patient neg/donor neg | 23 (17.3) |
| Patient neg/donor pos | 18 (13.5) |
| Patient pos/donor neg | 36 (27.1) |
| Patient pos/donor pos | 45 (33.8) |
| NE | 1 (0.8) |
| GVHD prophylaxis | |
| CsA plus mMtx | ‡23 (17.3) |
| CsA plus MMF | §¶108 (81.2) |
| Graft | |
| Source | |
| Bone marrow | 15 (11.3) |
| Peripheral blood | 116 (87.2) |
| Both | 2 (1.5) |
| Values | |
| Bone marrow | |
| WBC, × 108 cells/kg (15 pt) | 3.7 (1.9-14.0) |
| CD34, × 106 cells/kg (13 pt) | 3.0 (1.0-9.6) |
| CD3, × 108 cells/kg (11 pt) | 0.5 (0.2-2.4) |
| Peripheral blood | |
| WBC, × 108 cells/kg (114 pt) | 13.5 (4.2-32.7) |
| CD34, × 106 cells/kg (116 pt) | 6.7 (1.7-14.0) |
| CD3, × 108 cells/kg (108 pt) | 2.8 (1.1-6.6) |
| Both | |
| WBC, × 108 cells/kg (2 pt) | 35.2 |
| CD34, × 06 cells/kg (2 pt) | 2.5 |
| CD3, × 108 cells/kg (2 pt) | 3.3 |
Totals are numbers (%) except where defined otherwise. Graft cell values are given per kilogram of patient body weight.
CP indicates chronic phase; AP/BC, acute phase/blast crisis; CR, complete remission; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB/t, refractory anemia with excess blasts in transformation; CMMoL, chronic myelomonocytic leukemia; PR, partial remission; sAML, secondary AML; OMF, osteomyelofibrosis; neg, negative; pos, positive; NE, not evaluable; MMF, mycophenolate mofetil; WBC, white blood cells; and pt, patients.
ATG was used for conditioning in 1 patient.
Three patients did not receive ATG conditioning although ATG was used for conditioning in all unrelated donors.
Including 3 patients with additional ATG.
Including 60 patients with additional ATG.
Including 2 patients with additional prednisolone.